Azitra (AZTR) Accounts Payables (2022 - 2026)
Azitra (AZTR) reported Accounts Payables of $932217.0 for Q1 2026, up 66.79% on a YoY basis from $558924.0 in Q1 2025, and up 133.43% quarter-over-quarter from $399356.0 in Q4 2025.
Azitra (AZTR) Accounts Payables (2022 - 2026) Analysis & Trends
Azitra has reported Accounts Payables for 5 years, with the latest figure at $932217.0 in Q1 2026.
- For the quarter ending Q1 2026, Accounts Payables rose 66.79% year-over-year to $932217.0; the trailing twelve-month figure through Mar 2026 stood at $932217.0 (up 66.79% YoY), and the FY2025 full-year result was $399356.0, down 18.54% from the prior year.
- Accounts Payables for Q1 2026 stood at $932217.0, up from $399356.0 in the prior quarter.
- The five-year high for Accounts Payables was $996700.0 in Q2 2024, with the low at $364183.0 in Q2 2023.
- Historically, Accounts Payables has averaged $643642.7 across 5 years, with a median of $588460.0 in 2024.
- The largest YoY upside for Accounts Payables was 173.68% in 2024 against a maximum downside of 45.36% in 2024.
- Azitra's Accounts Payables stood at $784687.0 in 2022, then gained by 14.35% to $897272.0 in 2023, then tumbled by 45.36% to $490255.0 in 2024, then fell by 18.54% to $399356.0 in 2025, then soared by 133.43% to $932217.0 in 2026.
- The last three Accounts Payables figures came in at $932217.0 (Q1 2026), $399356.0 (Q4 2025), and $718476.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.05 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 83.00 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 8.64 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 489.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 34.55 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 932,217.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 932,217.00 |
| Dec 31, 2025 | 399,356.00 |
| Sep 30, 2025 | 718,476.00 |
| Jun 30, 2025 | 635,842.00 |
| Mar 31, 2025 | 558,924.00 |
| Dec 31, 2024 | 490,255.00 |
| Sep 30, 2024 | 588,460.00 |
| Jun 30, 2024 | 996,700.00 |
| Mar 31, 2024 | 583,055.00 |
| Dec 31, 2023 | 897,272.00 |
| Sep 30, 2023 | 417,928.00 |
| Jun 30, 2023 | 364,183.00 |
| Dec 31, 2022 | 784,687.00 |